Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
ab-101 (2 trials)
ab-201 (1 trial)
afm13 (1 trial)
aldesleukin (Proleukin) (2 trials)
cyclophosphamide (cytoxan) (3 trials)
fludarabine (fludara) (3 trials)
rituximab (rituxan) (1 trial)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Trials (3 total)
Trial APIs (7 total)